Brumm Joshua T
SEC-identified person · CIK 1528826 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Glycomimetics INC GLYC | Director · Chief Executive Officer | filed 2025 - 2026 |
| Dyne Therapeutics, Inc. DYN | Director · See Remarks | filed 2020 - 2024 |
| Kaleido Biosciences, Inc. KLDO | See Remarks | filed 2019 - 2019 |
| Versartis, Inc. VSAR | Chief Financial Officer | filed 2014 - 2017 |
| Pharmacyclics INC pcyc | EVP, Finance | filed 2012 - 2012 |
| Zeltiq Aesthetics Inc ZLTQ | VP of Corporate Development | filed 2011 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.